Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,239,275
-
Total 13F shares
-
3,121,706
-
Share change
-
-144,275
-
Total reported value
-
$98,400,000
-
Price per share
-
$31.52
-
Number of holders
-
29
-
Value change
-
+$1,688,330
-
Number of buys
-
18
-
Number of sells
-
9
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2017
As of 30 Sep 2017,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
29 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,121,706 shares.
The largest 10 holders included
FMR LLC, MENORA MIVTACHIM HOLDINGS LTD., HIGHLINE CAPITAL MANAGEMENT, L.P., WELLINGTON MANAGEMENT GROUP LLP, PERCEPTIVE ADVISORS LLC, JENNISON ASSOCIATES LLC, Wildcat Capital Management, LLC, CREDIT SUISSE AG/, DSAM Partners (London) Ltd, and BAINCO INTERNATIONAL INVESTORS.
This page lists
29
institutional shareholders reporting positions in this security
for the Q3 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.